Erythropoiesis-stimulating agents in the management of cancer patients with anemia: A meta-analysis

Chinese Journal of Cancer Research

Volumn 26, Issue 3, 2014, Pages 268-276

  Li, Xiaomei ^a   Yan, Zhi ^a   Kong, Dexiao ^a   Zou, Wen ^a   Wang, Jihua ^a   Sun, Dianshui ^a   Jiang, Yuhua ^a   Zheng, Chengyun ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Adverse events; Anemia; Cancer; Erythropoiesis stimulating agents (ESAs)

Indexed keywords

ANTIANEMIC AGENT; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; CANCER PATIENT; DRUG EFFICACY; ERYTHROCYTE TRANSFUSION; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERTENSION; META ANALYSIS; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; SOLID TUMOR; VENOUS THROMBOEMBOLISM;

EID: 84903893572     PISSN: 10009604     EISSN: 19930631     Source Type: Journal    
DOI: 10.3978/j.issn.1000-9604.2014.05.03     Document Type: Article

References (45)

1. Fields SZ, Parshad S, Anne M, et al. Activin receptor antagonists for cancer-related anemia and bone disease. Expert Opin Investig Drugs 2013;22:87-101.
2. Shabaruddin FH, Chen LC, Elliott RA, et al. A systematic review of utility values for chemotherapy-related adverse events. Pharmacoeconomics 2013;31:277-88.
3. Luo W, Nordstrom BL, Fraeman K, et al. Adherence to guidelines for use of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia: results of a retrospective study of an electronic medical-records database in the United States. Clin Ther 2008;30:2423-35.
4. Ludwig H, Van Belle S, Barrett-Lee P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40:2293-306. (Pubitemid 39348881)
5. Wauters I, Vansteenkiste J. Darbepoetin alfa in the treatment of anemia in cancer patients undergoing chemotherapy. Expert Rev Anticancer Ther 2012;12:1383-90.
6. Rodgers GM, Becker PS, Blinder M, et al. Cancer- and chemotherapy-induced anemia. J Natl Compr Canc Netw 2012;10:628-53.
7. Aapro M, Spivak JL. Update on erythropoiesis-stimulating agents and clinical trials in oncology. Oncologist 2009;14 Suppl 1:6-15.
8. Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-74. (Pubitemid 32538196)
9. Vansteenkiste J, Pirker R, Massuti B, et al. Doubleblind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94:1211-20. (Pubitemid 34993871)
10. Hedenus M, Adriansson M, San Miguel J, et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 2003;122:394-403. (Pubitemid 36951623)
11. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005;23:5960-72.
12. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebocontrolled trial. Lancet 2003;362:1255-60. (Pubitemid 37324251)
13. Bohlius J, Schmidlin K, Brillant C, et al. Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data. Cochrane Database Syst Rev 2009;(3):CD007303.
14. Tonia T, Mettler A, Robert N, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 2012;12:CD003407.
15. Thomas G, Ali S, Hoebers FJ, et al. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/ dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol Oncol 2008;108:317-25.
16. Hoskin PJ, Robinson M, Slevin N, et al. Effect of epoetin alfa on survival and cancer treatment-related anemia and fatigue in patients receiving radical radiotherapy with curative intent for head and neck cancer. J Clin Oncol 2009;27:5751-6.
17. Glaspy JA. Erythropoietin in cancer patients. Annu Rev Med 2009;60:181-92.
18. Paladini L, Clark O, Clark L, et al. Erythropoiesis stimulating agents (ESA) for the treatment of chemotherapy induced anemia in patients with hemoglobin levels (Hb)<11 g/dl- a systematic review and meta-analysis. Blood 2008;112:abstr 1305.
19. Olivo SA, Macedo LG, Gadotti IC, et al. Scales to assess the quality of randomized controlled trials: a systematic review. Phys Ther 2008;88:156-75. (Pubitemid 351210558)
20. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analysis. BMJ 2003;327:557-60.
21. Salanti G, Amountza G, Ntzani EE, et al. Hardy-weinberg equilibrium in gennetic association studies: An empirical evaluation of reporting, deviations, and power. Eur J Hum Genet 2005;13:840-8. (Pubitemid 40946083)
22. Cascinu S, Fedeli A, Del Ferro E, et al. Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo. J Clin Oncol 1994;12:1058-62. (Pubitemid 24145337)
23. Gordon D, Nichols G, Ben-Jacob A, et al. Treating anemia of cancer with every-4-week darbepoetin alfa: final efficacy and safety results from a phase II, randomized, double-blind, placebo-controlled study. Oncologist 2008;13:715-24. (Pubitemid 351904916)
24. Hernandez E, Ganly P, Charu V, et al. Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia. Curr Med Res Opin 2009;25:2109-20.
25. Tjulandin SA, Bias P, Elsasser R, et al. Epoetin Theta in Anaemic Cancer Patients Receiving Platinum-Based Chemotherapy: A Randomised Controlled Trial. Arch Drug Inf 2010;3:45-53.
26. Fujisaka Y, Sugiyama T, Saito H, et al. Randomised, phase III trial of epoetin-beta to treat chemotherapy-induced anaemia according to the EU regulation. Br J Cancer 2011;105:1267-72.
27. Tjulandin SA, Bias P, Elsasser R, et al. Epoetin Theta with a New Dosing Schedule in Anaemic Cancer Patients Receiving Nonplatinum-Based Chemotherapy: A Randomised Controlled Trial. Arch Drug Inf 2011;4:33-41.
28. Cabanillas ME, Kantarjian H, Thomas DA, et al. Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial. Cancer 2012;118:848-55.
29. Smith RE Jr, Aapro MS, Ludwig H, et al. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol 2008;26:1040-50.
30. Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med 2004;116 Suppl 7A:11S-26S.
31. Caro JJ, Salas M, Ward A, et al. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001;91:2214-21. (Pubitemid 32552805)
32. Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008;299:914-24. (Pubitemid 351397066)
33. Glaspy J, Crawford J, Vansteenkiste J, et al. Erythropoiesisstimulating agents in oncology: a study-level meta- analysis of survival and other safety outcomes. Br J Cancer 2010;102:301-15.
34. Hedenus M, Osterborg A, Tomita D, et al. Effects of erythropoiesis- stimulating agents on survival and other outcomes in patients with lymphoproliferative malignancies: a study-level meta-analysis. Leuk Lymphoma 2012;53:2151-8.
35. Aapro M, Jelkmann W, Constantinescu SN, et al. Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer. Br J Cancer 2012;106:1249-58.
36. Kang RY, Lee J, Lee YH, et al. Impact of erythropoiesis-stimulating agents on red blood cell transfusion in Korea. Int J Clin Pharm 2012;34:651-7.
37. Vadhan-Raj S, Zhou X, Sizer K, et al. Impact of safety concerns and regulatory changes on the usage of erythropoiesis-stimulating agents and RBC transfusions. Oncologist 2010;15:1359-69.
38. Boone JD, Fauci JM, Walters CL, et al. The effect of the APPRISE mandate on use of erythropoiesis-stimulating agents and transfusion rates in patients with ovarian cancer receiving chemotherapy. Int J Gynecol Cancer 2013;23:367-71.
39. Halstenson CE, Macres M, Katz SA, et al. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther 1991;50:702-12.
40. Storring PL, Tiplady RJ, Gaines Das RE, et al. Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Br J Haematol 1998;100:79-89. (Pubitemid 28051844)
41. Glaspy J, Henry D, Patel R, et al. Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa. Eur J Cancer 2005;41:1140-9. (Pubitemid 40725572)
42. Ohashi Y, Uemura Y, Fujisaka Y, et al. Meta-analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy-induced anemia and mortality: Individual patient data from Japanese randomized, placebo-controlled trials. Cancer Sci 2013;104:481-5.
43. Osterborg A, Aapro M, Cornes P, et al. Preclinical studies of erythropoietin receptor expression in tumour cells: impact on clinical use of erythropoietic proteins to correct cancer-related anaemia. Eur J Cancer 2007;43:510-9. (Pubitemid 46177584)
44. Sinclair AM, Rogers N, Busse L, et al. Erythropoietin receptor transcription is neither elevated nor predictive of surface expression in human tumour cells. Br J Cancer 2008;98:1059-67. (Pubitemid 351399799)
45. Paragh G, Kumar SM, Rakosy Z, et al. RNA interference-mediated inhibition of erythropoietin receptor expression suppresses tumor growth and invasiveness in A2780 human ovarian carcinoma cells. Am J Pathol 2009;174:1504-14.